When Chemo Kills: The Inside Story

When Chemo Kills

Prigerson is a professor at Weil Cornell Medical College and Harvard Medical School, and her co-authors are all professors at Columbia, Yale, Duke, Michigan, etc. Her report in JAMA Oncology created a bit of a stir in medical circles. To date, it has been referenced 200+ times in other journal articles (an indication of its impact).

In this paper, they spoke in unusually direct terms for academics:

The quality of life “in patients with end-stage cancer is not improved, and can be harmed, by chemotherapy use near death, even in patients with good performance status.”

Yet, aside from a few blogs or specialized websites, there was a virtual news blackout on this major study on the futility of palliative chemo. It had intrinsic merit. But reporters shied away from the topic, probably because it is depressing to learn that a major form of therapy is so counterproductive.

Difficulty Researching This Topic

There is in fact a systematic bias in the reporting of negative effects of chemo. To illustrate the problem, a PubMed search of the words benefit of cancer chemotherapy returned 22,645 citations to research papers. But a search of the words harm of cancer chemotherapy returned just 261 such citations, about 1% of the positive ones!

https://www.mossreports.com/when-chemo-kills/

The Only Book You Need When Help is Not On The Way

Home Doctor

Antibiotics can save your life but they are notoriously hard to stockpile if you don’t know about this ingenious method:

How to Stockpile Antibiotics Without a Prescription

It is completely legal and perfectly safe.

The best part is you can also use it for other medicines that require a prescription like insulin or Humira for example.

This is just one of the many ingenious tidbits of medical knowledge you’ll discover inside The Home Doctor: Practical Medicine for Every Household

This unique book was written by doctors to help people take care of their health ailments at home when the medical system cannot be depended on anymore.

It will prove vital in the next crisis, and you should check it out while it’s still available.

https://hop.clickbank.net/?affiliate=clickbktlg&vendor=homedoc&tid=blog

BOOM! It Is Unravelling!

SUMMARY: The infection fatality rate (IFR) of COVID-19… …analysis suggests global IFR of 0.03% for ages 0-59 and 0.07% for 0-69 years…

Less than a tenth of one percent!

ARTICLE: The infection fatality rate (IFR) of COVID-19 among non-elderly people in the absence of vaccination or prior infection is important to estimate accurately, since 94% of the global population is younger than 70 years and 86% is younger than 60 years. In systematic searches in SeroTracker and PubMed (protocol: https://osf.io/xvupr), we identified 40 eligible national seroprevalence studies covering 38 countries with pre-vaccination seroprevalence data. For 29 countries (24 high-income, 5 others), publicly available age-stratified COVID-19 death data and age-stratified seroprevalence information were available and were included in the primary analysis. The IFRs had a median of 0.035% (interquartile range (IQR) 0.013 – 0.056%) for the 0-59 years old population, and 0.095% (IQR 0.036 – 0.125%,) for the 0-69 years old. The median IFR was 0.0003% at 0-19 years, 0.003% at 20-29 years, 0.011% at 30-39 years, 0.035% at 40-49 years, 0.129% at 50-59 years, and 0.501% at 60-69 years. Including data from another 9 countries with imputed age distribution of COVID-19 deaths yielded median IFR of 0.025-0.032% for 0-59 years and 0.063-0.082% for 0-69 years. Meta-regression analyses also suggested global IFR of 0.03% and 0.07%, respectively in these age groups. The current analysis suggests a much lower pre-vaccination IFR in non-elderly populations than previously suggested. Large differences did exist between countries and may reflect differences in comorbidities and other factors. These estimates provide a baseline from which to fathom further IFR declines with the widespread use of vaccination, prior infections, and evolution of new variants.

https://www.medrxiv.org/content/10.1101/2022.10.11.22280963v1